These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 714218)

  • 21. [Therapeutic results with combination of pyridinolcarbamate and clofibrate in atherosclerotic patients].
    Valiensi M; Riboli E; Lombardi M
    Minerva Cardioangiol; 1976 Feb; 24(2):148-54. PubMed ID: 1256654
    [No Abstract]   [Full Text] [Related]  

  • 22. Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography.
    Motomiya T; Atsumi T; Isokane N; Yamashita S; Sano T
    Jpn Heart J; 1970 Sep; 11(5):433-49. PubMed ID: 4921577
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical and plethysmographic evaluation in patients with peripheral arteriopathies treated with pyridinolcarbamate].
    Lucero Eseverri JA; Fajardo JD; Velles Aguirre L; Quijano E; Ciliberti E; Lucarelli R
    Prensa Med Argent; 1970 Apr; 57(8):394-8. PubMed ID: 5517707
    [No Abstract]   [Full Text] [Related]  

  • 24. Pyridinolcarbamate, bradykinin antagonist, in patients suffering from arteriosclerosis obliterans and thromboangiitis obliterans (Buerger's disease); a preliminary report on the treatment of human atherosclerosis.
    Shimamoto T; Atsumi T
    Jpn Heart J; 1965 Sep; 6(5):407-15. PubMed ID: 5294603
    [No Abstract]   [Full Text] [Related]  

  • 25. A multiclinic double-blind trial of pyridinolcarbamate and inositol niacinate in ischemic ulcer due to chronic arterial occlusion.
    Mishima Y; Kamiya K; Sakaguchi S; Kusaba A; Sakuma A
    Angiology; 1977 Feb; 28(2):84-94. PubMed ID: 326097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of pyridinolcarbamate on blood coagulation and thrombolysis in patients with arteriosclerosis obliterans].
    Hess H; Goossens N; Keil-Kuri E; Zollner R; Meyer A
    Vasa; 1972; 1(3):206-11. PubMed ID: 5076123
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pharmacotherapy of peripheral arteriosclerosis].
    Belousov IuB; Savenkov PM; Sidel'man AA; Parfenov AS; Savenkov MP
    Kardiologiia; 1978 Aug; 18(8):36-43. PubMed ID: 99596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of atherosclerosis obliterans with pyridinolcarbamate.
    Atsumi T; Motomiya T; Isokane N; Shimamoto T
    Jpn Heart J; 1971 Jul; 12(4):335-46. PubMed ID: 5314713
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical and laboratory examinations with Prodectin.
    Bédi J; Kosztovics A; Pálos LA
    Ther Hung; 1976; 24(3):91-7. PubMed ID: 1013926
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect of angioprotectors on the glomerular filtration rate and vascular permeability in diabetic angiopathies].
    Tirkina TN; Mirkhodzhaev AKh; Alekseev IuP; Ionushas BS; Kasymova SD
    Probl Endokrinol (Mosk); 1979; 25(4):11-6. PubMed ID: 471968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of prodectin in the treatment of cerebral arteriosclerosis and its complications.
    Abrányi I; Máté
    Ther Hung; 1976; 24(1):20-3. PubMed ID: 790631
    [No Abstract]   [Full Text] [Related]  

  • 32. [Atheroid and anginin in diabetic retinopathy].
    Margolis MG; Zefirova GS; Shul'pina NB
    Vestn Oftalmol; 1973; 1():38-41. PubMed ID: 4130225
    [No Abstract]   [Full Text] [Related]  

  • 33. [Evaluation of the therapeutic effect of hyperbaric oxygenation and anginin in peptic ulcer].
    Elizavetina GA; Vinnitskiĭ LI; Vorob'eva NT; Chorbinskaia SA; Izmalkova NM
    Ter Arkh; 1989; 61(2):46-8. PubMed ID: 2543095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiatherogenic effect of pyridinolcarbamate (prodectin). Experimental study.
    Orbetzova V; Jurukova Z; Orbetzova M
    Artery; 1980; 8(6):560-9. PubMed ID: 7259535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacologic evaluation of the antiatherosclerotic agent, pyridinolcarbamate. A double-blind crossover trial in the treatment of atherosclerosis obliterans.
    Shimamoto T; Atsumi T; Yamashita S; Motomiya T; Isokane N; Ishioka T; Sakuma A
    Am Heart J; 1970 Jan; 79(1):5-19. PubMed ID: 4903137
    [No Abstract]   [Full Text] [Related]  

  • 36. Partial suppression by pyridinolcarbamate of growth and necrosis of atherosclerotic lesions in swine subjected to an atherogenic regimen that produces advanced lesions.
    Lee WM; Lee KT; Thomas WA
    Exp Mol Pathol; 1979 Feb; 30(1):85-93. PubMed ID: 421864
    [No Abstract]   [Full Text] [Related]  

  • 37. [Antithrombotic prophylaxis of the complications of arteriosclerosis obliterans].
    Heine H; Norden K; Heinemann L; Stepanauskas M; Schmidt H
    Kardiologiia; 1981 Aug; 21(8):76-80. PubMed ID: 7289389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Value of pyridinol carbamate in ocular vascular pathology (Angioxine)].
    Boudet ; Millet ; Arnaud
    Bull Soc Ophtalmol Fr; 1974; 74(9-10):977-80. PubMed ID: 4470033
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of arteriosclerosis obliterans with pyridinolcarbamate].
    Atsumi T; Isokane N; Yamashita S; Sano T; Odakura T; Kurai A
    Nihon Naika Gakkai Zasshi; 1967 Sep; 56(9):983-92. PubMed ID: 5627161
    [No Abstract]   [Full Text] [Related]  

  • 40. [Mechanism of action and clinical effectiveness of the new Soviet-made drug parmidin in the treatment of arteriosclerosis and ischemic heart disease].
    Kukes VG; Mashkovskiĭ MD; Paskhina TS; Borisov VG; Shvarts GIa
    Kardiologiia; 1978 Oct; 18(10):61-8. PubMed ID: 213636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.